Platinum ferrocenyl-phosphonate complexes [Fc(CH 2 have been characterized by X-ray structure determinations; moderate activity against P388 leukaemia cells is exhibited by 6 and 7, but the parent phosphonic acids are inactive. 
Introduction
Due to the efficacy of various platinum complexes as antitumour agents a wide variety of platinum complexes have been screened for antitumour activity. Among these are complexes containing phosphonate ligands, [1] which include, for example, complexes effective against osteosarcoma, a specificity believed to be due to the affinity of the phosphonate groups for calcified tissue.
[2] A wide range of platinum complexes containing aminophosphonate [3] and other phosphonate [4] ligands have been described in the literature, many of which have 3 antitumour activity. Relevant to the studies described in this paper, complexes of the type 1 were synthesised by Kemmitt and co-workers by the reaction of cis-[PtCl 2 L 2 ] (L= ancillary donor ligand, e.g. PPh 3 ) with the phosphonic acid or phosphoric acid monoester and excess Ag 2 O (as a halide abstracting agent and base). [5] In this paper we extend this methodology to the synthesis of platinum phosphonate complexes using ferrocene-derived phosphonic acids which we have recently reported. [6] 
Results and discussion

Synthesis and characterisation
Reactions of the ferrocenyl monophosphonic acids 2-4 with cis-[PtCl 2 (PPh 3 ) 2 ] and excess Ag 2 O in refluxing dichloromethane gives the platinum phosphonate complexes 5-7 respectively in high yield, Scheme 1, while the corresponding reaction with the bis(phosphonic acid) 8 gives the binuclear complex 9, Scheme 2. The products are air-stable pale yellow solids which crystallise with dichloromethane of crystallisation, and decompose when heated.
Complexes 5-7 are soluble in organic solvents such as dichloromethane and chloroform, while 9 is soluble in more polar solvents such as dimethylsulfoxide and methanol. In the case of 9, satisfactory elemental analyses could not be obtained, but confirmation of the product was achieved by NMR spectroscopy and an X-ray structure determination. The structures of 6, 7 and 9 were determined by single-crystal X-ray diffraction studies, in order to confirm the bonding mode of the phosphonate ligand, and to provide a comparison between three closely related complexes. Selected bond lengths and angles for the three structures are given in Tables 2 (6), 3 (7) and 4 (9), while the molecular structures and atom numbering schemes are given in Figures 1-3 respectively. Overall, the structure determinations were routine, and bond lengths and angles of the platinum-phosphonate moiety were consistent with those of [Pt(O 3 PPh)(PMePh 2 ) 2 ]. [5] The structure of 6, when compared to that of the free acid [6] shows only minor changes in bond angles and lengths upon coordination to platinum. Most notable are the reduction in the P=O bond length (1.566 Å in the free acid vs. 1.476 Å in 6), as the opportunity for hydrogen-bonding is removed, and the decrease in the O-P-O bond angle (108° in free acid vs. 101° in 12) due to the constrained nature of the four-membered Pt-O-P-O ring. The P=O bond lengths in all three structures are shorter than those of the metallacyclic P-O bonds. The cyclopentadienyl rings of the ferrocene group adopt an eclipsed conformation and the C(1)-C(11) bond lies in the plane of the cyclopentadienyl ring. 5 The principal difference in the structures of 6 and 7 lies in the orientation of the ferrocenyl unit with respect to the platinum coordination plane, as shown in Figure 4 . In 6, the ferrocenyl axis perpendicular to the cyclopentadienyl planes is almost parallel with the Pt…P(1) axis. This minimises steric interactions between the ferrocenyl group and the phenyl rings of the PPh 3 ligands. In contrast, for 7 the corresponding ferrocenyl axis lies at an angle of ca. 60° to the Pt.…P(1) axis. The additional CH 2 spacer in 7 reduces steric congestion between the ferrocenyl and PPh 3 groups, and the ferrocenyl group is subsequently able to adopt an orientation more strongly influenced by crystal packing forces than internal steric demands.
The cyclopentadienyl rings of 9 adopt a staggered conformation with the two PO 3 units in an anti configuration to minimise steric interactions ( Figure 5 ); the same configuration is also seen in the free acid. [6] The core of this complex is very nearly centrosymmetric about the Fe atom; bond lengths are essentially identical for the two halves of the molecule. The coordination planes of the platinum atoms are almost perpendicular to the plane of the ferrocenyl cyclopentadienyl rings.
All of the complexes possess a distorted platinum square plane. 
Antitumour activity
Given the interest in biological activity of platinum complexes [7] , phosphonate complexes [1], and ferrocene-based complexes [8] , the antitumour activity of the platinum phosphonate complexes described herein was considered worthy of preliminary investigation.
Samples of 6 and 7 were assayed for activity against P388 leukaemia cells, with the activity of the parent phosphonic acids FcCH 2 PO 3 H 2 and FcCH 2 CH 2 PO 3 H 2 also undertaken for comparison. IC 50 data are listed in Table 6 ; the phosphonic acids are essentially inactive, whereas the platinum complexes 6 and 7 show moderate activity.
Experimental
General experimental procedures were as described previously [6] ; reactions were carried out in solvents which were not deoxygenated. IR spectra were recorded as KBr disks. NMR spectra were recorded in CDCl 3 solution unless otherwise stated. The compounds cis-
, silver(I) oxide [10] , and the phosphonic acids [6] were prepared as described previously. The atom numbering schemes of the ferrocenyl groups is as previously reported. [6] Antitumour assays were carried out by the Marine Chemistry Group, University of Canterbury, NZ. The samples were dissolved in 1:3 dichloromethane-methanol (typically 5 mg mL -1 ; 2.5 mg mL -1 for 6), and a two-fold series of dilutions incubated for 72 hours with P388 (Murine Leukaemia) cells. The IC 50 value was determined by reduction of the yellow 7 dye MTT tetrazolium by healthy cells to the purple dye MTT formazan. Mitomycin C was used as a positive control.
Synthesis of platinum ferrocenylphosphonate complexes
The general method used was that described by Kemmitt et al.[5] 
Crystal structure determinations
Data for 6 were collected on a Nicolet R3 diffractometer at the University of Canterbury, while data for 7 and 9 were collected on a Siemens Smart CCD diffractometer at the University of Auckland, and corrected for absorption using SADABS. [11] The structures were solved by Patterson methods for platinum and iron and developed routinely using the SHELX-97 program [12] with full-matrix least-squares refinement based on F o 2 . The structures of 6 and 7 each include two independent dichloromethane molecules of
crystallisation. Complete refinement of 9 was hampered by the presence of disordered solvent molecules. A single methanol of crystallisation was successfully modelled but the final difference map contained several large peaks of electron density, some of which were able to be successfully modelled as carbon or oxygen atoms, but were unable to be refined in chemically sensible solvent molecules. Despite this, an acceptable R 1 of 0.0473 was achieved 10 and the structure of the platinum complex was refined without ambiguity. All non-hydrogen atoms were refined using anisotropic temperature factors, while hydrogen atoms were placed in calculated positions. Crystallographic data and analysis parameters for the three structures are given in Table 7 .
Crystallographic data (excluding structure factors) for the three structures have been deposited with the Cambridge Crystallographic Data Centre as supplementary publication nos.
CCDC-###### (6), ###### (7) and ###### (9) . Copies of the data can be obtained free of charge on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK (fax: (+44)1223-336-033; e-mail: deposit@ccdc.cam.ac.uk). 
